Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 4/20 | 0.57 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 5/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.42 |
| ▸ | CLK2 | P49760 | 4/20 | 0.42 |
| ▸ | CLK3 | P49761 | 3/20 | 0.42 |
| ▸ | GSK3B | P49841 | 3/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26436938 | 0.93 | EHMT2 (0.59) | EHMT2MAPK7NAMPTDYRK1ACLK2 | |
| SCHEMBL26436950 | 0.92 | EHMT2 (0.58) | EHMT2MAPK7NAMPTDYRK1ACLK2 | |
| SCHEMBL26436936 | 0.85 | EHMT2 (0.58) | EHMT2MAPK7NAMPTDYRK1ACLK2 | |
| SCHEMBL26439016 | 0.84 | EHMT2 (0.56) | EHMT2MAPK7NAMPTDYRK1ACLK2 | |
| SCHEMBL26436929 | 0.84 | EHMT2 (0.58) | EHMT2MAPK7NAMPTDYRK1ACLK2 | |
| SCHEMBL26438986 | 0.82 | EHMT2 (0.55) | EHMT2MAPK7NAMPTDYRK1ACLK2 | |
| SCHEMBL26436621 | 0.82 | EHMT2 (0.59) | EHMT2MAPK7NAMPTDYRK1ACLK2 | |
| SCHEMBL23421614 | 0.82 | EHMT2 (0.53) | EHMT2NAMPTDYRK1ACLK2CLK3 | |
| SCHEMBL23448624 | 0.81 | EHMT2 (0.58) | EHMT2MAPK7NAMPTDYRK1ACLK2 | |
| SCHEMBL26090547 | 0.81 | EHMT2 (0.59) | EHMT2MAPK7NAMPTDYRK1ACLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230127046-A1 | G9a INHIBITOR | EZH2, BMI1, DOT1L | EHMT2 8/4885MAPK7 2060/4885NAMPT 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.